Fig. 7

WEE1 kinase inhibition sensitizes human head and neck cancer cells to direct and ADCC-mediated NK cell lysis. a Loss of cell index of UMSCC-6 or − 9 cells following the addition of haNK cells at increasing E:T ratios was measured via real-time impedance analysis. Vertical line at ~ 24 h indicates time at which haNKs were added. Control cells were exposed to haNK media alone. % loss of cell index 24 h after the addition of haNKs is quantified on right. b UMSCC-6 and -9 cells were assessed for cell surface PD-L1 expression by flow cytometry in the presence of absence of IFN stimulation (10 μg/mL × 24 hours). c Loss of cell index following the addition of haNKs or healthy donor (HD) NK cells to UMSCC-6 (at 1:1 E:T ratio) or − 9 (10:1 E:T ratio) treated with Avelumab (2 ng/mL) or isotype control was measured via real-time impedance analysis. Where indicated, Avelumab was added at the same time haNK or HD NK cells were added. % loss of cell index 12 and 48 h after the addition of haNKs is quantified to the right of each plot. d Loss of cell index following the addition of haNKs to UMSCC-6 (at 1:1 E:T ratio) or − 9 (10:1 E:T ratio) treated with Avelumab or isotype control and plated in the presence or absence of AZD1775 (AZD) at 250 nM was measured via real-time impedance analysis. % loss of cell index 12 and 48 h after the addition of haNKs is quantified to the right of each plot. All in vitro experiments were repeated in at least three independent assays with similar results. *, p < 0.05; **, p < 0.01; ***, p < 0.001